AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Mar 17, 2021
31637_dirs_2021-03-16_95d6a704-ca7d-49ee-81a7-38b0cd490d6f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-03-15
Reporting Person: Krognes Steve E. (CFO and Treasurer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-15 | Common Stock | S | 13258 | $61.164 | Disposed | 886742 | Indirect |
| 2021-03-15 | Common Stock | S | 32326 | $62.043 | Disposed | 854416 | Indirect |
| 2021-03-15 | Common Stock | S | 3258 | $62.713 | Disposed | 851158 | Indirect |
| 2021-03-15 | Common Stock | S | 1158 | $63.67 | Disposed | 850000 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 97587 | Direct |
Footnotes
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.52 to $61.515 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $61.52 to $62.50 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $62.52 to $63.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F6: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $63.67 to $63.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F7: Includes 80,358 restricted stock units.